株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Effimune SAS - 製品パイプライン分析

Effimune SAS - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 311252
出版日 ページ情報 英文 22 Pages
即納可能
価格
こちらの商品の販売は終了いたしました。
Back to Top
Effimune SAS - 製品パイプライン分析 Effimune SAS - Product Pipeline Review - 2015
出版日: 2015年05月27日 ページ情報: 英文 22 Pages

当商品の販売は、2016年09月14日を持ちまして終了しました。

概要

Effimune SAS は、自己免疫および移植手術における免疫修飾治療薬を製造し、提供する有数のバイオテクノロジー企業です。同社の製品は、臓器及び組織の移植手術、また自己免疫疾患において、免疫システムを調整してくれます。

当レポートでは、Effimune SAS における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Effimune SASの基本情報

Effimune SASの概要

  • 主要情報
  • 企業情報

Effimune SAS:R&Dの概要

  • 主な治療範囲

Effimune SAS:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Effimune SAS:パイプライン製品の概況

  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ

Effimune SAS:薬剤プロファイル

  • FR-104
  • MD-707
  • MF-280
  • MP-196

Effimune SAS:パイプライン分析

  • 標的別
  • 分子タイプ別
  • 作用機序別

Effimune SAS:最近のパイプライン動向

Effimune SAS:本社と子会社の所在地

付録

図表一覧

目次
Product Code: GMDHC07133CDB

Summary

Global Markets Direct's, 'Effimune SAS - Product Pipeline Review - 2015', provides an overview of the Effimune SAS's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Effimune SAS's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Effimune SAS including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Effimune SAS's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Effimune SAS's pipeline products

Reasons to buy

  • Evaluate Effimune SAS's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Effimune SAS in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Effimune SAS's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Effimune SAS and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Effimune SAS
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Effimune SAS and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Effimune SAS Snapshot
    • Effimune SAS Overview
    • Key Information
    • Key Facts
  • Effimune SAS - Research and Development Overview
    • Key Therapeutic Areas
  • Effimune SAS - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Effimune SAS - Pipeline Products Glance
    • Effimune SAS - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Effimune SAS - Drug Profiles
    • EFFI-7H
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FR-104
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MF-280
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MP-196
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Effimune SAS - Pipeline Analysis
    • Effimune SAS - Pipeline Products by Target
    • Effimune SAS - Pipeline Products by Molecule Type
    • Effimune SAS - Pipeline Products by Mechanism of Action
  • Effimune SAS - Recent Pipeline Updates
  • Effimune SAS - Dormant Projects
  • Effimune SAS - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Effimune SAS, Key Information
  • Effimune SAS, Key Facts
  • Effimune SAS - Pipeline by Indication, 2015
  • Effimune SAS - Pipeline by Stage of Development, 2015
  • Effimune SAS - Monotherapy Products in Pipeline, 2015
  • Effimune SAS - Preclinical, 2015
  • Effimune SAS - Pipeline by Target, 2015
  • Effimune SAS - Pipeline by Molecule Type, 2015
  • Effimune SAS - Pipeline Products by Mechanism of Action, 2015
  • Effimune SAS - Recent Pipeline Updates, 2015
  • Effimune SAS - Dormant Developmental Projects,2015

List of Figures

  • Effimune SAS - Pipeline by Top 10 Indication, 2015
  • Effimune SAS - Pipeline by Top 10 Target, 2015
  • Effimune SAS - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top